Avience Biomedicals Ltd(AVIENCE)

NSE: AVIENCE

₹ 252+5.00%refreshed 26 Oct, 03:30 pm ISTMarket cap: ₹ 138 crWebsite: avienbio.com/Updated: 27 Oct 2026

About

Avience Biomedicals Ltd makes and trades medical devices and related products, including infectious disease diagnostic kits, serology products, biochemistry analysers and reagents, and reports them as a single business segment. Consolidated revenue from operations was ₹52.51 crore in FY26, up from ₹45.24 crore in FY25. Its shares were listed on the Nifty SME Emerge Index on June 25, 2026.^[1][2][3]

Business mix

The company reports one business segment, 'Medical devices and related products', covering both making and trading of these products (FY26).^[1]
Manufacturing brought in about 26.99% of turnover and trading about 72% in FY26, with service income making up the rest. Management describes the manufacturing-to-trading mix as about 30:70.^[2]

Products

The portfolio covers infectious disease diagnostic kits, serology products, biochemistry analysers and biochemistry reagents (FY26).^[1]
As of the Q4 FY26 call, the company held 88 product licences, had recently added 17 more products, and had over 200 products in its development and approval pipeline.^[2]
Under its closed-loop model, 80-90% of reagents are tied to its own instruments, and 80-85% of instruments are placed on reagent-rental terms (FY26).^[2]

Customers and distribution

The company supplies diagnostic products to healthcare providers and end users, both in India and abroad (FY26).^[1]
It is a Mindray channel partner for Delhi NCR and eastern UP. Talks are under way for exclusive North India rights on selected products and an OEM/private-label deal under the Avience name (Q4 FY26 call).^[2]
Foreign exchange earnings were Rs. 53.11 lakhs in FY26, down from Rs. 524.30 lakhs in FY25. Foreign exchange outgo was Rs. 58.19 lakhs, compared with Rs. 54.05 lakhs.^[1]
The company said it had exported about ₹70 - 80 lakh in the first three months of the fiscal year and is registering products in several overseas markets.^[2]

Order book

The company has an order of about ₹47 crore in hand, mainly for Uttarakhand, a new territory beyond Delhi NCR and eastern UP (Q4 FY26 call).^[2]

Expansion and capex

A new Biochemistry Analyser Plant is being built at Plot No.70, Sector 28, YEIDA, Greater Noida. It is funded by a SIDBI term loan of up to Rs. 1,200 lakhs (FY26).^[1]
The new facility is substantially complete. Remaining work is expected to finish by September 2026, with manufacturing targeted to start in October 2026.^[2]
The new facility can support peak revenue of about ₹250 crore, depending on product mix. Utilisation is expected at 15 - 20% in FY27.^[2]
Management targets about 175 approved products by the end of FY27 and a manufacturing-to-trading mix closer to 50:50 as in-house production grows.^[2]

Recent developments

The company's equity shares were listed on the Nifty SME Emerge Index on June 25, 2026. The company was formerly Avience Biomedicals Private Limited.^[1]

Market Cap

₹138 Cr

High / Low

₹415 / 222

Stock P/E

11.9

Price / Book

0.0

EPS

₹21.7

ROCE

23.2%

ROE

27.9%

OPM

26.5%

Debt / Equity

0.92

Sales

₹53 Cr

Net Profit

₹9 Cr

Promoter holding

64.6%

Loading chart…

Signal history

AI Deep Dive

The analysis Screener can't give you

Our models read the latest earnings call, annual report, and financials end-to-end - then grade management, value the business, and flag the risks. Unlock all of it for this company:

Verdict
The headline call - descriptive label, conviction, and the synthesis behind it.
Valuation
Guidance-anchored P&L bridge - worst / average / best multiple cases.
Walk the talk
Did management deliver on past guidance? A commitment-by-commitment scorecard.
Red flags
Forensic and governance risk pointers, severity-ranked.
Balance sheet
Solvency and earnings-quality score.
Concall briefs
Quarter-by-quarter earnings-call briefs - what changed and why.

₹49 unlocks this company for 90 days, ₹299 for a full year - bundles bring it lower. Built on public disclosures - educational, not investment advice.

AI Deep Dive

Verdict

Locked

The headline call - descriptive label, conviction, and the synthesis behind it.

Company data

Financials